The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a class 4 medicines defect information for Atnahs Pharma UK Limited, Naprosyn Tablets (all strengths) and Naprosyn EC 500mg Gastro-Resistant Tablets. Additional to the batches included in the previous Class 4 Medicines Notification (reference EL(22)A/05), Atnahs Pharma UK Limited have informed MHRA that the Patient Information Leaflets (PILs) in specified batches are missing information.
Further information on the affected batches, missing information and advice for healthcare professionals can be found on the MHRA website.
Want the latest pharmacy news and updates straight to your inbox?
Sign up to our regular newsletter for the latest guidance, news, events and CPD opportunities.